Identification of 5-fluorouracil response proteins in colorectal carcinoma cell line SW480 by two-dimensional electrophoresis and MALDI-TOF mass spectrometry

Oncology Reports

Volumn 20, Issue 1, 2008, Pages 89-98

  Wong, Cesar Sze Chuen ^a   Wai Ki Wong, Vicky ^a   Ming Lok Chan, Charles ^a   Buig Yue Ma, Brigette ^a   Pun Hui, Edwin ^a   Chi Keung Wong, Manson ^b   Yan Yee Lam, Money ^a   Chi Chuen, Thomas ^a   Chan, Wing Han ^a   Cheuk, Wah ^b   Tak Cheung Chan, Anthony ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

5 fluorouracil response proteins; Colorectal cancer; Mass spectrometry; SW480; Two dimensional electrophoresis

Indexed keywords

ALPHA ENOLASE; BETA ACTIN; CARBAMOYL PHOSPHATE SYNTHASE; CARBAMOYL PHOSPHATE SYNTHASE1; CELL PROTEIN; CYCLOPHILIN A; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 8; CYTOKERATIN 9; FLUOROURACIL; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 70; NUCLEOSIDE DIPHOSPHATE KINASE NM23; PEROXIREDOXIN; PEROXIREDOXIN 6; RAN PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; HEAT SHOCK PROTEIN; HSPB1 PROTEIN, HUMAN; KERATIN; NME4 PROTEIN, HUMAN; TUMOR PROTEIN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; PROTEOMICS; TWO DIMENSIONAL ELECTROPHORESIS; CHEMISTRY; COLORECTAL TUMOR; DOSE RESPONSE; IMMUNOHISTOCHEMISTRY; MASS SPECTROMETRY; TUMOR CELL LINE; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FLUOROURACIL; HEAT-SHOCK PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; NEOPLASM PROTEINS; NM23 NUCLEOSIDE DIPHOSPHATE KINASES; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 49849090629     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.20.1.89     Document Type: Article

References (76)

1. Liu X, Lazenby AJ and Siegal GP: Signal transduction cross-talk during colorectal tumorigenesis. Adv Anat Pathol 13: 270-274, 2006.
2. Allen WL and Johnston PG: Have we made progress in pharmacogenomics? The implementation of molecular markers in colon cancer. Pharmacogenomics 6: 603-614, 2005.
3. Moertel CG: Chemotherapy for colorectal cancer. N Engl J Med 330: 1136-1142, 1994.
4. Chau I and Cunningham D: Chemotherapy in colorectal cancer: new options and new challenges. Br Med Bull 64: 159-180, 2002.
5. Wulfkuhle JD, Liotta LA and Petricoin EF: Proteomic applications for the early detection of cancer. Nat Rev Cancer 3: 267-275, 2003.
6. Ahram M, Best CJ, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF III and Emmert-Buck MR: Proteomics analysis of human prostate cancer. Mol Carcinog 33: 9-15, 2002.
7. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC and Liotta LA: Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359: 572-577, 2002.
8. Li J, Zhang Z, Rosenzweig J, Wang YY and Chan DW: Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48: 1296-1304, 2002.
9. Xiao X, Liu D, Tang Y, Guo F, Xia L, Liu J and He D: Development of proteomic patterns for detecting lung cancer. Dis Markers 19: 33-39, 2004.
10. Chen ST, Pan LT, Tsai YC and Huang CM: Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett 181: 95-107, 2002.
11. Gehrmann ML, Fenselau C and Hathout Y: Highly altered protein expression profile in the adriamycin resistant MCF-7 cell line. J Proteome Res 3: 403-409, 2004.
12. Urbani A, Poland J, Bernardini S, Bellincampi L, Biroccio A, Schnolzer M, Sinha P and Federici G: A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines. Proteomics 5: 796-804, 2005.
13. Shaw PE: Peptidyl-prolyl isomerases: a new twist to transcription. EMBO Rep 3: 521-526, 2002.
14. Luban J, Bossolt KL, Franke EK, Kalpana GV and Goff SP: Human-immunodeficiency-virus type-1 gag protein binds to cyclophilin A and cyclophilin B. Cell 73: 1067-1078, 1993.
15. Galat A: Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity-targets-functions. Curr Top Med Chem 3: 1315-1347, 2003.
16. Melle C, Osterloh D, Ernst G, Schimmel B, Bleul A and von Eggeling F: Identification of proteins from colorectal cancer tissue by two-dimensional gel electrophoresis and SELDI mass spectrometry. Int J Mol Med 16: 11-17, 2005.
17. Campa MJ, Wang MZ, Howard B, Fitzgerald MC and Patz EF Jr: Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res 63: 1652-1656, 2003.
18. Bouwens L, Lu WG and De Krijger R: Proliferation and differentiation in the human fetal endocrine pancreas. Diabetologia 40: 398-404, 1997.
19. Deshpande V, Fernandez-del Castillo C, Muzikansky A, Deshpande A, Zukerberg L, Warshaw AL and Lauwers GY: Cytokeratin 19 is a powerful predictor of survival in pancreatic endocrine tumors. Am J Surg Pathol 28: 1145-1153, 2004.
20. Erkilic S and Kocer NE: The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease. Endocr Pathol 16: 63-66, 2005.
21. Pujol JL, Grenier J, Parrat E, Lehmann M, Lafontaine T, Quantin X and Michel FB: Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS. Am J Respir Crit Care Med 154: 725-733, 1996.
22. Inokuchi M, Ninomiya I, Tsugawa K, Terada I and Miwa K: Quantitative evaluation of metastases in axillary lymph nodes of breast cancer. Br J Cancer 89: 1750-1756, 2003.
23. Gadducci A, Ferdeghini M, Cosio S, Fanucchi A, Cristofani R and Genazzani AR: The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer. Int J Gynecol Cancer 11: 277-282, 2001.
24. Sanchez-Carbayo M, Espasa A, Chinchilla V, Herrero E, Megias J, Mira A and Soria F: New electrochemiluminescent immunoassay for the determination of CYFRA 21-1: analytical evaluation and clinical diagnostic performance in urine samples of patients with bladder cancer. Clin Chem 45: 1944-1953, 1999.
25. Uenishi T, Kubo S, Hirohashi K, Tanaka H, Shuto T, Yamamoto T and Nishiguchi S: Cytokeratin-19 fragments in serum (CYFRA 21-1) as a marker in primary liver cancer. Br J Cancer 88: 1894-1899, 2003.
26. Gires O, Andratschke M, Schmitt B, Mack B and Schaffrik M: Cytokeratin 8 associates with the external leaflet of plasma membranes in tumour cells. Biochem Biophys Res Commun 328: 1154-1162, 2005.
27. Ku NO, Azhar S and Omary MB: Keratin 8 phosphorylation by p38 kinase regulates cellular keratin filament reorganization: modulation by a keratin 1-like disease causing mutation. J Biol Chem 277: 10775-10782, 2002.
28. Fukunaga Y, Bandoh S, Fujita J, Yang Y, Ueda Y, Hojo S, Dohmoto K, Tojo Y, Takahara J and Ishida T: Expression of cytokeratin 8 in lung cancer cell lines and measurement of serum cytokeratin 8 in lung cancer patients. Lung Cancer 38: 31-38, 2002.
29. Wennerberg K, Rossman KL and Der CJ: The ras superfamily at a glance. J Cell Sci 118: 843-846, 2005.
30. Milano J Jr and Strayer DS: Effects of overexpression of Ran/TC4 mammalian cells in vitro. Exp Cell Res 239: 31-39, 1998.
31. Li H, Ren CP, Tan XJ, Yang XY, Zhang HB, Zhou W and Yao KT: Identification of genes related to nasopharyngeal carcinoma with the help of pathway-based networks. Acta Biochim Biophys Sin 38: 900-910, 2006.
32. Pemberton LF and Paschal BM: Mechanisms of receptor-mediated nuclear import and nuclear export. Traffic 6: 187-198, 2005.
33. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E and Kroemer G: Heat shock proteins 27 and 70: anti-apoptotic proteins with tumorigenic properties. Cell Cycle 5: 2592-2601, 2006.
34. Ferns G, Shams S and Shafi S: Heat shock protein 27: its potential role in vascular disease. Int J Exp Pathol 87: 253-274, 2006.
35. O'Neill PA, Shaaban AM, West CR, Dodson A, Jarvis C, Moore P, Davies MP, Sibson DR and Foster CS: Increased risk of malignant progression in benign proliferating breast lesions defined by expression of heat shock protein 27. Br J Cancer 90: 182-188, 2004.
36. Morino M, Tsuzuki T, Ishikawa Y, Shirakami T, Yoshimura M, Kiyosuke Y, Matsunaga K, Yoshikumi C and Saijo N: Specific expression of HSP27 in human tumor cell lines in vitro. In Vivo 11: 179-184, 1997.
37. Luk JM, Lam CT, Siu AF, Lam BY, Ng IO, Hu MY, Che CM and Fan ST: Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics 6: 1049-1057, 2006.
38. Nakajima M, Kuwano H, Miyazaki T, Masuda N and Kato H: Significant correlation between expression of heat shock proteins 27, 70 and lymphocyte infiltration in esophageal squamous cell carcinoma. Cancer Lett 178: 99-106, 2002.
39. Miyazaki T, Kato H, Faried A, Sohda M, Nakajima M, Fukai Y, Masuda N, Manda R, Fukuchi M, Ojima H, Tsukada K and Kuwano H: Predictors of response to chemo-radiotherapy and radiotherapy for esophageal squamous cell carcinoma. Anticancer Res 25: 2749-2755, 2005.
40. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL and Soini Y: Peroxiredoxins in breast carcinoma. Clin Cancer Res 9: 3418-3424, 2003.
41. Kinnula VL, Lehtonen S, Sormunen R, Kaarteenaho-Wiik R, Kang SW, Rhee SG and Soini Y: Overexpression of peroxiredoxins I, II, III, V and VI in malignant mesothelioma. J Pathol 196: 316-323, 2002.
42. Quan C, Cha EJ, Lee HL, Han KH, Lee KM and Kim WJ: Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J Urol 175: 1512-1516, 2006.
43. Fujita Y, Nakanishi T, Hiramatsu M, Mabuchi H, Miyamoto Y, Miyamoto A, Shimizu A and Tanigawa N: Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin Cancer Res 12: 6415-6420, 2006.
44. Faried A, Sohda M, Nakajima M, Miyazaki T, Kato H and Kuwano H: Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma. Eur J Cancer 40: 2804-2811, 2004.
45. Hanlon JG, Adams K, Rainbow AJ, Gupta RS and Singh G: Induction of Hsp60 by photofrin-mediated photodynamic therapy. J Photochem Photobiol B 64: 55-61, 2001.
46. Urushibara M, Kageyama Y, Akashi T, Otsuka Y, Takizawa T, Koike M and Kihara K: HSP60 may predict good pathological response to neoadjuvant chemoradiotherapy in bladder cancer. Jpn J Clin Oncol 37: 56-61, 2007.
47. Moll R, Franke W, Schiller D, Geiger B and Krepler R: The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumours and cultured cells. Cell 31: 11-24, 1982.
48. Starzinski-Powitz A, Gaetje R, Zeitvogel A, Kotzian S, Handrow-Metzmacher H, Herrmann G, Fanning E and Baumann R: Tracing cellular and molecular mechanisms involved in endometriosis. Hum Reprod Update 4: 724-729, 1998.
49. Blaheta RA, Kronenberger B, Woitaschek D, Auth MK, Scholz M, Weber S, Schuldes H, Encke A and Markus BH: Dedifferentiation of human hepatocytes by extracellular matrix proteins in vitro: quantitative and qualitative investigation of cytokeratin 7, 8, 18, 19 and vimentin filaments. J Hepatol 28: 677-690, 1998.
50. Prochasson P, Gunther M, Laithier M, Fossar N, Lavialle C and Brison O: Transcriptional mechanisms responsible for the overexpression of the keratin 18 gene in cells of a human colon carcinoma cell line. Exp Cell Res 248: 243-259, 1999.
51. Schaller G, Fuchs I, Pritze W, Ebert A, Herbst H, Pantel K, Weitzel H and Lengyel E: Elevated keratin 18 protein expression indicates a favorable prognosis in patients with breast cancer. Clin Cancer Res 2: 1879-1885, 1996.
52. Moll R, Levy R, Czernobilsky B, Hohlweg-Majert P, Dallenbach-Hellweg G and Franke WW: Cytokeratins of normal epithelia and some neoplasms of the female genital tract. Lab Invest 49: 599-610, 1983.
53. Knapp AC, Franke WW, Heid H, Hatzfeld M, Jorcano JL and Moll R: Cytokeratin No.9, an epidermal type I keratin characteristic of a special program of keratinocyte differentiation displaying body site specificity. J Cell Biol 103: 657-667, 1986.
54. Swensson O, Langbein L, McMillan JR, Stevens HP, Leigh IM, McLean WH, Lane EB and Eady RA: Specialized keratin expression pattern in human ridged skin as an adaptation to high physical stress. Br J Dermatol 139: 767-775, 1998.
55. Ryall J, Nguyen M, Bendayan M and Shore GC: Expression of nuclear genes encoding the urea cycle enzymes, carbamoyl-phosphate synthetase I and ornithine carbamoyl transferase, in rat liver and intestinal mucosa. Eur J Biochem 152: 287-292, 1985.
56. Liu TH, Li DC, Gu CF and Ye SF: Carbamoyl phosphate synthetase I. A novel marker for gastric carcinoma. Chin Med J 102: 630-638, 1989.
57. Kinoshita M and Miyata M: Underexpression of mRNA in human hepatocellular carcinoma focusing on eight loci. Hepatology 36: 433-438, 2002.
58. Chang GC, Liu KJ, Hsieh CL, Hu TS, Charoenfuprasert S, Liu HK, Luh KT, Hsu LH, Wu CW, Ting CC, Chen CY, Chen KC, Yang TY, Chou TY, Wang WH, Whang-Peng J and Shih NY: Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res 12: 5746-5754, 2006.
59. Chang YS, Wu W, Walsh G, Hong WK and Mao L: Enolase-alpha is frequently down-regulated in non-small cell lung cancer and predicts aggressive biological behavior. Clin Cancer Res 9: 3641-3644, 2003.
60. Ejeskar K, Krona C, Caren H, Zaibak F, Li L, Martinsson T and Ioannou PA: Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death. BMC Cancer 5: 161, 2005.
61. Jaattela M: Escaping cell death: survival proteins in cancer. Exp Cell Res 248: 30-43, 1999.
62. Atkins D, Lichtenfels R and Seliger B: Heat shock proteins in renal cell carcinomas. Contrib Nephrol 148: 35-56, 2005.
63. Isomoto H, Oka M, Yano Y, Kanazawa Y, Soda H, Terada R, Yasutake T, Nakayama T, Shikuwa S, Takeshima F, Udono H, Murata I, Ohtsuka K and Kohno S: Expression of heat shock protein (Hsp) 70 and Hsp 40 in gastric cancer. Cancer Lett 198: 219-228, 2003.
64. Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M and Hirohashi S: Expression profiling in multistage hepato-carcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology 37: 198-207, 2003.
65. Kanazawa Y, Isomoto H, Oka M, Yano Y, Soda H, Shikuwa S, Takeshima F, Omagari K, Mizuta Y, Murase K, Nakagoe T, Ohtsuka K and Kohno S: Expression of heat shock protein (Hsp) 70 and Hsp 40 in colorectal cancer. Med Oncol 20: 157-164, 2003.
66. Nanbu K, Konishi I, Mandai M, Kuroda H, Hamid AA, Komatsu T and Mori T: Prognostic significance of heat shock proteins HSP70 and HSP90 in endometrial carcinomas. Cancer Detect Prev 22: 549-555, 1998.
67. Pocaly M, Lagarde V, Etienne G, Ribeil JA, Claverol S, Bonneu M, Moreau-Gaudry F, Guyonnet-Duperat V, Hermine O, Melo JV, Dupouy M, Turcq B, Mahon FX and Pasquet JM: Overexpression of the heat-shock protein 70 is associated to imatinib resistance in chronic myeloid leukemia. Leukemia 21: 93-101, 2007.
68. Rashmi R, Kumar S and Karunagaran D: Ectopic expression of Hsp70 confers resistance and silencing its expression sensitizes human colon cancer cells to curcumin-induced apoptosis. Carcinogenesis 25: 179-187, 2004.
69. Roigas J, Wallen ES, Loening SA and Moseley PL: Effects of combined treatment of chemotherapeutics and hyperthermia on survival and the regulation of heat shock proteins in Dunning R3327 prostate carcinoma cells. Prostate 34: 195-202, 1998.
70. Fournier HN, Albiges-Rizo C and Block MR: New insights into Nm23 control of cell adhesion and migration. J Bioenerg Biomembr 35: 81-87, 2003.
71. Martinez JA, Prevot S, Nordlinger B, Nguyen TM, Lacarriere Y, Munier A, Lascu I, Vaillant JC, Capeau J and Lacombe ML: Overexpression of nm23-H1 and nm23-H2 genes in colorectal carcinomas and loss of nm23-H1 expression in advanced tumour stages. Gut 37: 712-720, 1995.
72. Seifert M, Welter C, Mehraein Y and Seitz G: Expression of the nm23 homologues nm23-H4, nm23-H6, and nm23-H7 in human gastric and colon cancer. J Pathol 205: 623-632, 2005.
73. Popow A, Nowak D and Malicka-Blaszkiewicz M: Actin cytoskeleton and beta-actin expression in correlation with higher invasiveness of selected hepatoma Morris 5123 cells. J Physiol Pharmacol 57: 111-123, 2006.
74. Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV and Lenz HJ: Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer 6: 214-218, 2006.
75. Nowak D, Skwarek-Maruszewska A, Zemanek-Zboch M and Malicka-Blaszkiewicz M: Beta-actin in human colon adenocarcinoma cell lines with different metastatic potential. Acta Biochim Pol 52: 461-468, 2005.
76. Nowak D, Krawczenko A, Dus D and Malicka-Blaszkiewicz M: Actin in human colon adenocarcinoma cells with different metastatic potential. Acta Biochim Pol 49: 823-828, 2002.